BerandaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$6,78
Rentang hari
$6,23 - $7,60
Rentang tahun
$3,32 - $12,70
Kapitalisasi pasar
234,39 jt USD
Volume Rata-Rata
20,79 rb
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,55 jt | 273,73% |
Biaya operasional | 4,44 jt | -4,84% |
Laba bersih | -15,08 jt | 5,66% |
Margin laba bersih | -972,40 | 74,76% |
Penghasilan per saham | — | — |
EBITDA | -15,37 jt | -0,62% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 159,13 jt | -27,07% |
Total aset | 170,62 jt | -25,98% |
Total liabilitas | 15,05 jt | -38,62% |
Total ekuitas | 155,57 jt | — |
Saham yang beredar | 33,18 jt | — |
Harga terhadap nilai buku | 1,45 | — |
Tingkat pengembalian aset | -22,42% | — |
Tingkat pengembalian modal | -24,17% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -15,08 jt | 5,66% |
Kas dari operasi | -15,72 jt | -18,38% |
Kas dari investasi | 13,15 jt | 225,87% |
Kas dari pembiayaan | -267,00 rb | 2,55% |
Perubahan kas bersih | -2,66 jt | 75,12% |
Arus kas bebas | -9,80 jt | -15,75% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
162
